GMG

GMG Provides Details of 2023 AGM To Be Held Virtually

Retrieved on: 
Monday, October 16, 2023
MUST, GMG, Pacific Standard, Telephone, AGM, Computershare, Growth, Proxy, The Company, Circular, Annual general meeting, Nightclub, Security (finance), Holding company

BRISBANE, AUS, Oct 16, 2023 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is providing details of its upcoming Annual Meeting of shareholders ("AGM") to be held virtually on Tuesday, November 27, 2023, at 8:00 a.m. Brisbane Australian Eastern Standard Time (being Monday, November 26, 2023 at 2:00 p.m. (Canadian Pacific Standard Time).

Key Points: 
  • BRISBANE, AUS, Oct 16, 2023 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is providing details of its upcoming Annual Meeting of shareholders ("AGM") to be held virtually on Tuesday, November 27, 2023, at 8:00 a.m. Brisbane Australian Eastern Standard Time (being Monday, November 26, 2023 at 2:00 p.m. (Canadian Pacific Standard Time).
  • The AGM will be held in a virtual format, allowing shareholders to have an equal opportunity to participate at the AGM online regardless of their geographic location.
  • Attendees who have registered for the AGM as a "Guest" will not have the ability to vote at the AGM or ask questions.
  • GMG thanks the outgoing directors for their role in the growth of GMG, and wishes them all the best in their future endeavours.

Muscular Dystrophy Association Celebrates FDA Approval of ZILBRYSQ® zilucoplan for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients

Retrieved on: 
Wednesday, October 18, 2023
GMG, FDA, UCB, University, MDA, Muscular Dystrophy Association, Physician, US Foods, News, Pediatrics, Eyelid, Disease, Acetylcholine receptor, Patient, Doctor of Philosophy, Associate, Agonal respiration, Pharmaceutical industry

New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.

Key Points: 
  • New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
  • Zilucoplan is the first once-daily subcutaneous, targeted C5 complement inhibitor for gMG, and it is the only once-daily gMG-target therapy for self-administration.
  • "The recent approval of zilucoplan is great news for people living with gMG,” said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.
  • “This is the second gMG therapy out of UCB that has achieved FDA approval this year, providing patients and physicians with important options.

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

Retrieved on: 
Tuesday, October 17, 2023
Neonatal Fc receptor, UCB, MuSK protein, Food, MG, University of North Carolina at Chapel Hill, MAC, System, Disease, Immunoglobulin G, Hospital, Plasmapheresis, Oklahoma Office of the Chief Medical Examiner, Brussels Stock Exchange, NMJ, GMG, Diarrhea, Physician, RAISE, U.S. FDA, Neuromuscular junction, University, Safety, Lancet Neurology, Patient, The Lancet, Week, MD, Allied health professions, Myasthenia, Quality of life, Muscle weakness, Acetylcholine receptor, Travel, QMG, Neuromuscular disease, Fatigue, FDA, Upper respiratory tract infection, Pathology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Priority review, ACHR, Weakness, Pharmaceutical industry, Vaccine, Medicine, Neurology, C5

It is the only once-daily gMG target therapy for self-administration by adult patients with anti-AChR antibody-positive gMG.

Key Points: 
  • It is the only once-daily gMG target therapy for self-administration by adult patients with anti-AChR antibody-positive gMG.
  • Patients were randomized in a 1:1 ratio to receive daily subcutaneous injections of 0.3 mg/kg ZILBRYSQ or placebo for 12 weeks.
  • The most common adverse reactions (≥10%) in patients with gMG were injection site reactions, upper respiratory tract infection, and diarrhea.
  • The primary endpoint for the RAISE study was change from baseline to Week 12 in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) score.

GMG Announces New Chief Financial Officer

Retrieved on: 
Thursday, October 5, 2023
PWC, Commercial director, Alison Paterson (company director), Graphene, Partner, Commerce, Interim, University, Finance, Australian Institute of Company Directors, Energy, GMG, Master of Business Administration, Business administration, Battery, CFO, The Company, CIMIC Group, University of Oxford, Construction, Management

BRISBANE, AUS, Oct 5, 2023 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to advise that Brandon Leong has been appointed Chief Financial Officer (CFO) effective 17th October 2023.

Key Points: 
  • BRISBANE, AUS, Oct 5, 2023 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to advise that Brandon Leong has been appointed Chief Financial Officer (CFO) effective 17th October 2023.
  • The Company would like to thank Scott Richardson who has been Interim Chief Financial Officer (CFO) since 31 July, 2023 and has led the finance team through the recent capital raise and year end audit process as well as implemented a number of improvement initiatives and will work through to the end of January 2024 to ensure a smooth handover to Brandon.
  • Brandon comes with CFO role experience drawing on over 20 years of financial leadership roles including as CFO, Deputy CFO, Financial and Commercial Director and Financial Advisory roles in publicly listed, private companies and advisory firms - including PWC in Australia and United States of America, CPB Contractors (Construction), Aurizon (Rail), Holcim (Construction Materials) and various other companies.
  • GMG's 4 critical business objectives remain to:
    Produce Graphene and improve/scale the production processBuild Revenue from Energy Savings ProductsDevelop Next-Generation Battery Develop Supply Chain, Partners & Project Execution Capability

Speaker of The Australian House of Representatives Hon Milton Dick MP Officially Opens THERMAL-XR(R) Blending Plant

Retrieved on: 
Wednesday, October 4, 2023
Sumner, Queensland, Partner, GMG, Federal, Energy, The Company, Representative, Speaker of the Australian House of Representatives, House, Nanotechnology, Graphene

Vancouver, BC, Oct 4, 2023 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to advise that the Honourable Milton Dick Member for Oxley and Speaker of The Australian House of Representatives officially opened the THERMAL-XR(R) Coating Blending Plant on Thursday 28th September 2023.

Key Points: 
  • Vancouver, BC, Oct 4, 2023 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to advise that the Honourable Milton Dick Member for Oxley and Speaker of The Australian House of Representatives officially opened the THERMAL-XR(R) Coating Blending Plant on Thursday 28th September 2023.
  • To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/182891_b23c9806d42a9932_001fu...
    Honourable Milton Dick said, "This blend plant represents a substantial investment in both technology and talent, featuring the latest advancements in nanotechnology coating production processes and quality control measures.
  • The plant's opening is a testament to GMG's focus to develop into a world-leading energy-saving product manufacturing business."
  • Speaker Milton Dick visited GMG at its Sumner Park location in 2020.

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

Retrieved on: 
Thursday, September 21, 2023
Hair, University, Lancet Neurology, FC, Muscular dystrophy, GMG, Efgartigimod alfa, Netherlands, Sale, Muscular Dystrophy Canada, Euronext, Patient, University of Toronto, Division, ADAPT, Immunoglobulin G, SE, University Health Network, Acetylcholine receptor, Neonatal Fc receptor, Health Canada, The Lancet, Pharmaceutical industry, Neurology

With this regulatory milestone, VYVGART is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada.

Key Points: 
  • With this regulatory milestone, VYVGART is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada.
  • “There continues to be a significant unmet medical need for people living with gMG, who face debilitating muscle weakness and mobility issues.
  • The gMG community in Canada has long awaited new effective treatment advancements for this rare condition.
  • “Today is an important day for us as we deliver on our commitment to the gMG community to make VYVGART available to patients in Canada,” said John Haslam, General Manager argenx Canada.

GMG Achieves Initial 500 mAh Graphene Aluminium-Ion Battery Prototype in Pouch Cell Format & Provides Next Steps Toward Commercialisation

Retrieved on: 
Monday, September 11, 2023
Mah, University, GMG, Cell, Level 4, The Company, Battery, UQ, Graphene, Electric battery, Lithium

The Company has now made initial G+AI Battery prototype pouch cells (see Figure 1), which have a storage capacity of over 500 mAh, with a nominal voltage of ~ 2 volts.

Key Points: 
  • The Company has now made initial G+AI Battery prototype pouch cells (see Figure 1), which have a storage capacity of over 500 mAh, with a nominal voltage of ~ 2 volts.
  • The next step for the Company is to optimise the assembly techniques of the pouch cell prototypes.
  • This is to achieve repeatable storage capacity of over 500 mAh cells in order to conduct a variety of standard testing conditions for comparative purposes.
  • Performance results for the pouch cells could be significantly different and will be communicated upon successfully producing a 1000 mAh+ battery pouch cell, and testing has been completed.

Graphene Manufacturing Group Appoints Former Wall Street Veteran and Manufacturing Entrepreneur Jack Perkowski to Its Board of Directors

Retrieved on: 
Friday, September 8, 2023
Investment banking, Paine Webber, Bain Capital, ASIMCO, Wall Street, GMG, ASIMCO Technologies, The Company, UBS, Knowledge, Investment, Chair, Management

BRISBANE, AUS, Sept 8, 2023 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV:GMG) ("GMG" or the "Company") is pleased to advise that Mr Jack Perkowski, based in New Jersey USA, has joined the Company's board of directors effective 7 September, 2023.

Key Points: 
  • BRISBANE, AUS, Sept 8, 2023 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV:GMG) ("GMG" or the "Company") is pleased to advise that Mr Jack Perkowski, based in New Jersey USA, has joined the Company's board of directors effective 7 September, 2023.
  • Mr Perkowski founded ASIMCO Technologies in 1994, and from 1994 to 2008, served as the Chairman of ASIMCO's Board of Directors and the company's Chief Executive Officer.
  • After leaving ASIMCO, Mr Perkowski founded JFP Holdings, a merchant banking firm focused on China, where he now serves as Chairman.
  • Guy Outen, GMG's Chair added, "I'm delighted to welcome Jack to the board.

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

Retrieved on: 
Friday, September 15, 2023
1991 World Sportscar Championship, IV, Marketing, SC, GMG, European Medicines Agency, Committee for Medicinal Products for Human Use, Quality of life, Committee, EMA, Euronext, Patient, Physician, ADAPT, Autoimmune disease, Ghent University, Immunoglobulin G, SE, Acetylcholine receptor, Ghent University Hospital, EC, CHMP, Pharmaceutical industry, Vaccine

SC efgartigimod is formulated with Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous delivery of biologics.

Key Points: 
  • SC efgartigimod is formulated with Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous delivery of biologics.
  • “Generalized myasthenia gravis is a complex and devastating disease that is debilitating for people who live with it, making routine movements exhausting and challenging to perform,” said Prof. dr. Jan De Bleecker, Ghent University Hospital and Ghent University.
  • The positive CHMP opinion is a scientific recommendation for marketing authorization, serving as a basis for the EC’s final decision on argenx’s application for SC efgartigimod.
  • The decision will apply to all 27 European Union Member States, and also to Iceland, Norway and Liechtenstein.

Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH

Retrieved on: 
Tuesday, September 12, 2023
Complement component 1s, Multifocal motor neuropathy, CIDP, Therapy, Half-life, GMG, Pathology, Myasthenia gravis, MMN, Patient, Dianthus, Vaccine, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced positive top-line Phase 1 data for DNTH103 validating its best-in-class potential as a selective classical pathway inhibitor targeting only the active form of the C1s protein. Additionally, Dianthus will begin trading on the Nasdaq Capital Market today as DNTH, following the successful completion on September 11, 2023 of the previously announced merger with Magenta Therapeutics (“Magenta”).

Key Points: 
  • Additionally, Dianthus will begin trading on the Nasdaq Capital Market today as DNTH, following the successful completion on September 11, 2023 of the previously announced merger with Magenta Therapeutics (“Magenta”).
  • The Phase 1 healthy volunteer study was designed to validate the extended half-life, potent classical pathway inhibition, and potentially differentiated safety profile of DNTH103.
  • Additional information about our Phase 1 data and DNTH103 can be found in our corporate presentation at investor.dianthustx.com .
  • “These results, combined with our transition to the public markets, represent a major milestone in our growth trajectory.